Certican 0

DRUG4 trials

Sponsors

Universitair Medisch Centrum Groningen, Universitair Medisch Centrum Groningen, Hospices Civils De Lyon, Universitair Medisch Centrum Groningen, Les Hopitaux Universitaires De Strasbourg

Conditions

COVID-19Herpes ZosterRenal Transplantationimpaired immunitykidney transplantkidney transplantation

Phase 2

Immunosuppression regimen reduction in kidney transplantation recipients admitted to the intensive care unit in the setting of septic shock and/or acute respiratory failure: an open multicentric randomized phase IV study

Not yet recruitingCTIS2024-518493-14-00

Les Hopitaux Universitaires De Strasbourgkidney transplant

Target: 212Updated: 2025-11-19

Phase 3

Prospective Randomized trial of Everolimus replacing MMF/MP Acid by the RECOVAC consortium to increase VACcine response in kidney transplant patients

CompletedCTIS2023-503894-39-00

Universitair Medisch Centrum Groningen, Universitair Medisch Centrum GroningenCOVID-19, Herpes Zoster, impaired immunity +1

Start: 2023-08-22End: 2024-02-27Target: 110Updated: 2023-10-10

Phase 4

Efficiency of everolimus for the treatment of kidney transplanted patients presenting a missing self-induced NK-mediated rejection (STARR)

RecruitingCTIS2024-513814-37-00

Hospices Civils De LyonRenal Transplantation

Start: 2020-12-03Target: 20Updated: 2024-09-30

The OPTIMIzE study;OPen label multicenter randomized Trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients.

CompletedCTIS2024-516509-22-00

Universitair Medisch Centrum Groningenkidney transplant

Start: 2019-07-22End: 2025-04-14Target: 381Updated: 2024-11-12